Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study

ConclusionIpragliflozin was effective and well tolerated in Japanese patients with T2DM over 12  months in the real-world clinical setting. Improvements in liver function parameters (AST and ALT) were observed in T2DM patients with abnormal liver function.Trial RegistrationClinicalTrials.gov identifier, NCT02479399.FundingAstellas Pharma Inc., Japan.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research